BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy